comparemela.com

Latest Breaking News On - Steven chiu - Page 1 : comparemela.com

Transcripts For CNBC Squawk Alley 20171016

We are going to talk to Kevin Hassett in just a few moments. Top story today, political pressure mounting on big tech yet again. Two Democratic Senators expected to unveil a bill this week which would require companies to disclose more information about political ads they run online. Ad says company reps prepare to testify before congress in a couple of weeks. Joining us this morning, Aneesh Chopra, who served as the chief Technology Officer during the Obama Administration hes in washington, d. C. , today. Good to have you back, good morning. Thanks for having me. You have these companies under pressure in the press, these meetings on capitol hill everybody except shareholders, it seems what do you think the repercussions are going to be . Well, we have two trends that are going to be difficult for the tech sector to manage. One is the issue of parody we have regulations that occur in the offline world, like political ad regulations on broadcast that have not yet been applied in the on

[Webinar] No Surprises Act Update: The Latest Litigation, Enforcement, IDR and Implementation Challenges - March 7th, 1:00 pm - 2:00 pm ET | Manatt, Phelps & Phillips, LLP

Three years after the No Surprises Act (NSA) was enacted, industry stakeholders and government regulators alike are still navigating the intricate twists and turns of the wide-ranging.

[Webinar] Creating Provider-Sponsored Medicare Advantage Plans: Opportunities, Risks and Keys to Success - July 20th, 1:00 pm - 2:00 pm ET | Manatt, Phelps & Phillips, LLP

Provider-sponsored plans are increasingly popular with hospitals, health systems and medical groups/independent physician associations (IPAs). Offering a plan can deliver many.

NEB Offers New Route to Amplify DNA Without Labor-Intensive Purification Steps

New England Biolabs (NEB) just announced its new Q5® Blood Direct 2X Master Mix. This latest DNA polymerase master mix amplifies a wide variety of genetic targets directly from whole or dried blood — without the need for costly and time-intensive purification steps.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.